Autolus Therapeutics
AUTL
55 hedge funds and large institutions have $177M invested in Autolus Therapeutics in 2019 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 14 increasing their positions, 14 reducing their positions, and 3 closing their positions.
400% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 3
28% more funds holding
Funds holding: 43 → 55 (+12)
6% more capital invested
Capital invested by funds: $167M → $177M (+$10.2M)
0% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 14
0.05% less ownership
Funds ownership: 29.89% → 29.84% (-0.05%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Schroder Investment Management Group
London,
United Kingdom
|
+$27.4M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$6.45M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.12M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$2.27M |
| 5 |
JP Morgan Chase
New York
|
+$500K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$9.42M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.73M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.3M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$859K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$615K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ED
51
Exane Derivatives
Paris,
France
| $2.29K | -$38.1K | -2,908 | -94% |
|
52
Daiwa Securities Group
Tokyo,
Japan
| $2K | – | – | – |
|
|
PA
53
Parallel Advisors
San Francisco,
California
| $2K | +$1.52K | +116 | New |
|
|
CSS
54
Cubist Systematic Strategies
Stamford,
Connecticut
| $1K | +$1.11K | +85 | New |
|
|
WIM
55
Woodford Investment Management
London,
United Kingdom
| – | -$26M | -2,095,127 | Closed |
|
|
EC
56
EcoR1 Capital
San Francisco,
California
| – | -$859K | -69,155 | Closed |
|
57
Allianz Asset Management
Munich,
Germany
| – | -$553K | -45,000 | Closed |
|
58
Barclays
London,
United Kingdom
| – | -$41.6K | -3,177 | -99% |
|
AUTL Hedge Fund Activity: Q4 2019 in Review
55 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q4 2019, worth a combined $177M — up 6.1% from $167M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new AUTL positions and 3 closed out — a net gain of 12 holders — while 14 added to existing stakes and 14 trimmed.
The largest buyer was Schroder Investment Management Group, opening a new position worth an estimated $27.4M. The largest seller was Millennium Management, cutting an estimated $9.42M.
- 55 institutional investors held Autolus Therapeutics (AUTL) as of Q4 2019, up from 43 in Q3 2019.
- Funds reported $177M of Autolus Therapeutics stock for Q4 2019, up 6.1% quarter-over-quarter.
- 15 funds opened new Autolus Therapeutics positions in Q4 2019 and 3 closed out, a net change of +12 holders.
- The largest Autolus Therapeutics buyer in Q4 2019 was Schroder Investment Management Group, an estimated $27.4M added.
- The largest Autolus Therapeutics seller in Q4 2019 was Millennium Management, an estimated $9.42M sold.
Based on aggregated 13F filings for Q4 2019.